Medical researchers develop new treatments for retinal damage and blindness

Recent medical research has introduced two distinct approaches to addressing vision loss and retinal damage.

An investigational oral drug, danegaptide, developed by Breye Therapeutics, has shown promise in preclinical studies for preventing or slowing diabetic retinopathy. The small molecule drug aims to protect retinal blood vessels from damage caused by high blood glucose by targeting cell-cell connections to maintain vessel integrity. This could provide a non-invasive alternative to current treatments, such as anti-VEGF injections, which are typically administered after significant damage has already occurred.

Separately, researchers at Aarhus University have developed injectable nanoparticles designed to restore light sensitivity in blind retinas. These hollow graphitic carbon nitride particles, inspired by plant chloroplasts, bypass damaged photoreceptors to directly stimulate surviving retinal nerve cells. In preclinical trials involving mice and pig tissue, the nanoparticles successfully triggered visual signals to the brain without the need for genetic modification or invasive electronic implants.